glp-1 nature receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease With Berberine Mapping the effectiveness and risks

Asia Pacific is expected to host the fastest-growing GLP-1 drugs market during the forecast period

In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg

Simultaneous determination of trimethylamine N-oxide, choline, betaine by UPLC-MS/MS in human plasma: an application in acute stroke patients

Selenium (as Sodium Selenate)